Defects in bile acid biosynthesis--diagnosis and treatment.

Bile acid synthetic defects represent a specific category of metabolic liver disease. This article highlights the history and summarizes our analytical approach to the diagnosis and treatment of genetic defects in bile acid synthesis. By the application of mass spectrometry as a screening tool, it is possible to perform rapid diagnosis of potential inborn errors in bile acid synthesis from urinary bile acid analysis. Molecular techniques then afford the identification of specific mutations in genes encoding the enzymes responsible for bile acid synthesis. Using this approach, 6 of the 7 known genetic defects that are causes of progressive cholestatic liver disease, syndromes of fat-soluble vitamin malabsorption, or neurological disease, have been characterized. Bile-acid therapy using oral cholic acid has proven effective in most of these bile acid synthetic defects making early diagnosis crucial to optimum clinical prognosis.

[1]  Jeffrey B. Cheng,et al.  Molecular Genetics of 3β-Hydroxy-Δ5-C27-Steroid Oxidoreductase Deficiency in 16 Patients with Loss of Bile Acid Synthesis and Liver Disease , 2003 .

[2]  F. Suchy,et al.  Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. , 1988, The Journal of clinical investigation.

[3]  B. Strandvik,et al.  DEFECTIVE BILE ACID AMIDATION: PREDICTED FEATURES OF A NEW INBORN ERROR OF METABOLISM , 1988, The Lancet.

[4]  Celeste Eng,et al.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. , 2002, The Journal of clinical investigation.

[5]  A. Moser,et al.  Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. , 2003, Gastroenterology.

[6]  I. Björkhem,et al.  Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid. , 1980, The Journal of clinical investigation.

[7]  N. Le,et al.  Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis. , 1989, Journal of lipid research.

[8]  M. Afschrift,et al.  Lipid-lowering effects of procetofene. , 1977 .

[9]  L. V. Bogaert,et al.  Une forme cérébrale de la cholestérinose généralisée : type particulier de lipidose à cholestérine , 1937 .

[10]  J. Heubi,et al.  Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (Δ4‐3‐oxosteroid 5β‐reductase deficiency) , 1993 .

[11]  K. Setchell,et al.  Oral bile acid treatment and the patient with zellweger syndrome , 1992, Hepatology.

[12]  P. Clayton,et al.  3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology , 1992, Journal of Inherited Metabolic Disease.

[13]  G. Tint,et al.  Cholic acid biosynthesis: the enzymatic defect in cerebrotendinous xanthomatosis. , 1979, The Journal of clinical investigation.

[14]  P. Meier,et al.  Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. , 1997, European journal of biochemistry.

[15]  R. Wanders,et al.  Multiple peroxisomal enzymatic deficiency disorders. A comparative biochemical and morphologic study of Zellweger cerebrohepatorenal syndrome and neonatal adrenoleukodystrophy. , 1986, The American journal of pathology.

[16]  A. Hofmann,et al.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis , 2005, Digestive Diseases and Sciences.

[17]  J. Sjövall,et al.  Mass spectrometry of bile acids. , 1985, Methods in enzymology.

[18]  K. Bove,et al.  Bile Acid Synthetic Defects and Liver Disease , 2000, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[19]  G. Salen,et al.  Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.

[20]  D. Russell,et al.  Bile acid biosynthesis. , 1992, Biochemistry.

[21]  H. Moser,et al.  Infantile Refsum's disease: Biochemical findings suggesting multiple peroxisomal dysfunction , 1986, Journal of Inherited Metabolic Disease.

[22]  K. S. Kim,et al.  Novel homozygous and compound heterozygous mutations of sterol 27-hydroxylase gene (CYP27) cause cerebrotendinous xanthomatosis in three Japanese patients from two unrelated families. , 1997, Journal of lipid research.

[23]  P. Clayton,et al.  Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. , 1990, Archives of disease in childhood.

[24]  R. Wevers,et al.  Mutations in the sterol 27-hydoxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis , 2002, Journal of Inherited Metabolic Disease.

[25]  A. Larghi,et al.  Clinical Pharmacokinetics of Therapeutic Bile Acids , 1996, Clinical pharmacokinetics.

[26]  U. Francke,et al.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. , 1991, The Journal of biological chemistry.

[27]  G. Tint,et al.  A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain. , 1974, The Journal of clinical investigation.

[28]  J. C. van der Molen,et al.  Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[29]  P. Clayton,et al.  Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. , 1987, The Journal of clinical investigation.

[30]  J. Sjövall,et al.  Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatorgaphy-mass spectrometry. , 1977, Journal of lipid research.

[31]  W. Lim,et al.  Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT , 2003, Nature Genetics.

[32]  P. Scambler,et al.  Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. , 2003, Gut.

[33]  A. Hofmann,et al.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis part II , 1982, Digestive Diseases and Sciences.

[34]  P. Clayton,et al.  Familial giant cell hepatitis associated with synthesis of 3β,7α-dihydroxy- and 3β,7α,12α-trihydroxy-5-cholenoic acid , 1987 .

[35]  R. Lathe,et al.  Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. , 1998, The Journal of clinical investigation.

[36]  R. Preisig,et al.  Monohydroxy bile salt sulfates: Tauro-3β-hydroxy-5-cholenoate-3-sulfate induces intrahepatic cholestasis in rats , 1983 .

[37]  S. Grundy,et al.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. , 1973, The Journal of clinical investigation.